Baird Medical Drives U.S. Market Penetration with Commercial Launch at Bakersfield Memorial Hospital
MWN-AI** Summary
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has announced a significant milestone in its U.S. market expansion with the commercial launch of its microwave ablation (MWA) technology at Bakersfield Memorial Hospital in California. This event marks the inaugural application of Baird Medical's proprietary platform for treating benign thyroid tumors in the San Joaquin Valley, a crucial healthcare hub in Central California.
The first procedure was successfully conducted by Dr. Tim Beck, an accomplished Endocrine Surgeon at Dignity Health Medical Group. This case not only demonstrated the capabilities of Baird Medical’s advanced technology but also confirmed the system’s efficiency and safety in a real-world clinical setting, emphasizing the company's commitment to enhancing patient care through innovative solutions.
Baird Medical’s strategy involves equipping healthcare institutions like Bakersfield Memorial with state-of-the-art tools that foster the adoption of interventional therapies. This initiative aligns with the company’s broader objective to improve the standard of care while driving growth in core regional markets across the United States.
As a leader in minimally invasive device technology, Baird Medical is well-positioned in the industry, having successfully implemented its solutions in more than 30 prestigious hospitals nationwide, including renowned institutions such as the Mayo Clinic and UCSF Medical Center. Furthermore, Baird Medical leads the market in China regarding thyroid microwave ablation devices and is actively expanding its global presence.
Overall, Baird Medical’s strategic launch at Bakersfield Memorial represents a pivotal step forward in the company's efforts to improve patient access to innovative medical care while paving the way for further expansion throughout the U.S. healthcare landscape.
MWN-AI** Analysis
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has made significant strides in enhancing its U.S. market penetration through the recent commercial launch of its minimally invasive Microwave Ablation (MWA) technology at Bakersfield Memorial Hospital. This strategic deployment signifies not only the introduction of innovative healthcare solutions in an essential market but also marks a pivotal moment for Baird Medical as it amplifies its presence within the competitive landscape of medical devices.
The successful ablation procedure performed under the expertise of Dr. Tim Beck solidifies Baird Medical's claims regarding its high-efficiency and safety-oriented technology. As the medical community increasingly shifts towards minimally invasive procedures, Baird's technology aligns well with this trend, answering demand for safer and efficient treatment options. This launch at a notable institution apart from enhancing patient access is likely to establish a strong referral network that could boost utilization rates for Baird's platforms.
Investors should note that Baird Medical's advancements are taking place in the broader context of a rapidly evolving healthcare sector, driven by technological innovations. Moreover, with a demonstrated foothold in the international arena, especially as a leader in China’s thyroid ablation market, Baird Medical is well-positioned to capitalize on global growth prospects.
However, it is essential to consider potential risks, including regulatory challenges and competitive pressures that could impact ongoing operations and expansion efforts. As always, while forward-looking statements may promise optimistic growth potential, investors should approach with prudent caution, remaining aware of the inherent uncertainties involved.
In conclusion, Baird Medical's strategic launch at Bakersfield Memorial Hospital presents a promising injection of interest for investors, particularly those looking toward healthcare technology advancements. Monitoring growth performance, competitive positioning, and regulatory landscapes will be critical in evaluating its long-term investment viability.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets.
The inaugural procedure was successfully performed by Tim Beck, M.D., a distinguished Endocrine Surgeon at Dignity Health Medical Group. Under Dr. Beck's direction, the clinical team utilized Baird Medical's proprietary platform to deliver precise, minimally invasive outcomes. The procedure demonstrated the system's high-efficiency ablation capabilities and favorable safety profile, validating the technology's value in a high-volume hospital setting.
This launch represents a focused execution of Baird Medical's commercial roadmap. By equipping institutions like Bakersfield Memorial with next-generation tools, the Company continues to drive the adoption of interventional therapies, enhancing the standard of care for patients while delivering on its growth objectives.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
SOURCE BDMD
FAQ**
How does the successful commercial launch of Baird Medical Investment Holdings Ltd (BDMD) at Bakersfield Memorial Hospital position the company for further market penetration in the U.S. medical device sector?
What specific strategies is Baird Medical Investment Holdings Ltd (BDMD) employing to expand its presence in key U.S. regions following the deployment at Bakersfield Memorial Hospital?
Can Baird Medical Investment Holdings Ltd (BDMD) provide insights into the expected patient outcomes and long-term benefits resulting from the use of their Microwave Ablation technology at Bakersfield Memorial Hospital?
What challenges does Baird Medical Investment Holdings Ltd (BDMD) anticipate while scaling its operations in the U.S. market, particularly in the wake of the surgical advancements showcased at Bakersfield Memorial Hospital?
**MWN-AI FAQ is based on asking OpenAI questions about Baird Medical Investment Holdings Ltd (NASDAQ: BDMD).
NASDAQ: BDMD
BDMD Trading
-0.73% G/L:
$2.73 Last:
357,720 Volume:
$2.75 Open:
